Use of berberine in preparation of medicine for preventing and treating radiation-induced intestinal injury
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SICHUAN INST OF ATOMIC ENERGY
- Filing Date
- 2026-06-15
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of effective drugs in the current technology for the prevention and treatment of radiation-induced intestinal injury, especially the problems caused by ionizing radiation, such as damage to the intestinal mucosal barrier, oxidative stress, increased levels of reactive oxygen species, inhibition of hematopoietic function, impaired proliferation of intestinal epithelial cells, intestinal flora imbalance, and excessive release of inflammatory factors.
Bergenin is used as the active ingredient to prepare oral, injectable or sustained-release/microsphere loaded formulations for relieving oxidative stress, improving the intestinal mucosal barrier, reducing inflammatory response and promoting intestinal flora balance. It is administered orally or by gavage at a dose of 20-30 mg/kg/day with a purity of ≥98%.
Bergenin can significantly reduce radiation-induced intestinal damage, repair intestinal mucosal structure, restore epithelial cell proliferation capacity, improve hematopoietic and immune functions, inhibit the expression of inflammatory factors, restore intestinal flora balance, and systematically repair metabolic imbalance, making it suitable for the prevention and treatment of radiation-induced intestinal damage.
Smart Images
Figure CN122398786A_ABST